CD33 28z CAR-T cells

CD33 28z CAR-T cells are autologous or allogeneic T cells that have been genetically modified to express a chimeric antigen receptor (CAR) targeting **CD33**, a cell surface antigen expressed on the majority of **acute myeloid leukemia (AML)** blasts and myeloid progenitor cells. The “28z” designation refers to the intracellular signaling domains CD28 (a co-stimulatory molecule) and CD3ζ (essential for T-cell activation), which enhance the proliferation, persistence, and cytotoxic function of engineered T cells. The CAR construct utilizes an anti-CD33 single-chain variable fragment (scFv) derived from antibodies such as lintuzumab or HuM-195. Preclinical studies and early phase clinical trials have demonstrated that CD33 28z CAR-T cells can induce potent anti-AML activity in vitro and in vivo, leading to depletion of CD33+ leukemic cells but also pose risks of myelosuppression due to targeting normal myeloid cells. Modifications, such as addition of safety switches or elimination genes, have been used to mitigate on-target/off-tumor toxicity. This cell therapy is being studied in children, adolescents, and adults with relapsed or refractory AML[1][3][4][6].

Other names

CD33CARTCD-33CARTCD 33CARTCD33-CD28/CD3ζ CAR-Tlintuzumab-CD28/CD3ζ CAR-THuM195-28z CAR-THuM-195-28z CAR-THuM 195-28z CAR-T